Simultaneous inference on treatment effects in survival studies with factorial designs

A clinical trial with a 2×2 factorial design involves randomization of subjects to treatment A or A‾ and, within each group, further randomization to treatment B or B‾. Under this design, one can assess the effects of treatments A and B on a clinical endpoint using all patients. One may additionally compare treatment A, treatment B, or combination therapy AB to A‾B‾. With multiple comparisons, however, it may be desirable to control the overall type I error, especially for regulatory purposes. Because the subjects overlap in the comparisons, the test statistics are generally correlated. By accounting for the correlations, one can achieve higher statistical power compared to the conventional Bonferroni correction. Herein, we derive the correlation between any two (stratified or unstratified) log-rank statistics for a 2×2 factorial design with a survival time endpoint, such that the overall type I error for multiple treatment comparisons can be properly controlled. In addition, we allow for adjustment of prognostic factors in the treatment comparisons and conduct simultaneous inference on the effect sizes. We use simulation studies to show that the proposed methods perform well in realistic situations. We then provide an application to a recently completed randomized controlled clinical trial on alcohol dependence. Finally, we discuss extensions of our approach to other factorial designs and multiple endpoints.

[1]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[2]  M. Akritas,et al.  Nonparametric inference in factorial designs with censored data. , 1996, Biometrics.

[3]  D. Cox Regression Models and Life-Tables , 1972 .

[4]  Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. , 2014, European heart journal.

[5]  W. Willett,et al.  The 2 x 2 factorial design: its application to a randomized trial of aspirin and carotene in U.S. physicians. , 1985, Statistics in medicine.

[6]  Edgar Brunner,et al.  Nonparametric Methods for Factorial Designs with Censored Data , 1997 .

[7]  M. Mardiney,et al.  Alteration of cellular ribonucleases associated with murine oncogenic virus infection. , 1978, Biomedicine / [publiee pour l'A.A.I.C.I.G.].

[8]  L. J. Wei,et al.  Regression analysis of multivariate incomplete failure time data by modeling marginal distributions , 1989 .

[9]  R. Peto,et al.  Clinical trial methodology , 1978, Nature.

[10]  W. Willett,et al.  The 2 × 2 factorial design: Its application to a randomized trial of aspirin and U.S. physicians , 1985 .

[11]  E V Slud Analysis of factorial survival experiments. , 1994, Biometrics.

[12]  N L Geller,et al.  The analysis of multiple endpoints in clinical trials. , 1987, Biometrics.

[13]  R. Gill,et al.  Cox's regression model for counting processes: a large sample study : (preprint) , 1982 .

[14]  John D. Kalbfleisch,et al.  The Statistical Analysis of Failure Data , 1986, IEEE Transactions on Reliability.

[15]  D A Follmann,et al.  Monitoring pairwise comparisons in multi-armed clinical trials. , 1994, Biometrics.

[16]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data: Kalbfleisch/The Statistical , 2002 .

[17]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[18]  David Couper,et al.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. , 2006, JAMA.

[19]  Garnet L Anderson,et al.  The women's health initiative: lessons learned. , 2008, Annual review of public health.

[20]  Richard J. Cook,et al.  Multiplicity Considerations in the Design and Analysis of Clinical Trials , 1996 .